Latest current cash for CDXC: $67M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Chromadex (CDXC) currently reports a current cash of $67M as of March 2026. That compares with $56M in the prior-year period — up 19.7% year over year. Use the charts on this page to explore Chromadex's current cash history and peer comparisons.
Chromadex's current cash increased from $56M to $67M — a 19.7% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Chromadex reported $67M in current cash as of March 2026. That compares with $56M in the prior-year period — up 19.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current current cash of $67M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Chromadex, and consider following CDXC for alerts when major investors trade the stock.
Chromadex is classified in the Healthcare sector. On current cash, it currently shows $67M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CDXC with unrelated industries.